{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 28 of 129', 'Since TCS represent the mainstay of pharmacological treatment of AD, many patients may', 'use tralokinumab in combination with TCS and this trial is intended to inform about treatment', 'and maintenance with concomitant use of tralokinumab and TCS. After a 16-week initial', 'treatment period, the trial will evaluate 2 different treatment options for additional 16-weeks', 'of maintenance therapy in the continuation treatment period (tralokinumab 300 mg Q2W and', '300 mg every 4 weeks [Q4W]).', 'The primary objective of this trial is to demonstrate that tralokinumab in combination with', 'TCS provides more effective control of the skin manifestations of AD than placebo in', 'combination with TCS. The trial will evaluate the percentage of subjects achieving IGA', 'response of 0 (clear) or 1 (almost clear) and the percentage of subjects achieving at least 75%', 'reduction in EASI score (EASI75) at Week 16, with secondary endpoints addressing symptom', 'scores and extent of AD (SCORAD), itch severity, and health-related quality of life (HRQoL)', 'measures related to AD.', 'Thus, the trial will further contribute to the characterisation of the benefit-risk profile of', 'tralokinumab.', '5.4 Justification for dose', 'The dose selected for the tralokinumab phase 3 development programme is 300 mg Q2W', 'administered subcutaneously. All subjects randomised to treatment with tralokinumab will get', 'an initial loading dose of 600 mg on Day 0 (baseline). The administration of the loading dose', 'of tralokinumab will allow systemic concentrations to reach steady-state faster, and', 'potentially reduce the time to onset of clinical effect. The serum concentrations of', 'tralokinumab after the 600 mg loading dose will not exceed the serum tralokinumab', 'concentrations at steady state for the 300 mg Q2W.', 'The tralokinumab 300 mg Q2W dose was chosen based on the results of the phase 2b trial in', 'subjects with moderate-to-severe AD (trial D2213C00001) described in Section 5.2. The', 'subjects were treated with 3 different fixed dose regimens of tralokinumab (45, 150, or', '300 mg Q2W) or placebo to evaluate safety and efficacy over a treatment period of 12 weeks.', 'In the overall intention-to-treat phase 2b population, a statistically significant improvement in', 'EASI change from baseline at Week 12 was observed in the tralokinumab 300 mg group', 'versus placebo; however, formal statistical significance was not demonstrated for the', 'co-primary endpoint IGA. The key secondary and exploratory endpoint results from', 'trial D2213C00001 also supported the selection of the tralokinumab Q2W 300 mg dose for', 'phase 3 development; and overall, larger numerical differences were observed for 300 mg', 'tralokinumab dose than for 150 mg compared to placebo for most of the trial endpoints.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 29 of 129', 'Since the safety profile in trial D2213C00001 was acceptable in all treatment cohorts and no', 'clear safety related dose-response pattern was identified, the dose of 300 mg Q2W has been', 'selected for evaluation in the phase 3 development programme for tralokinumab in AD.', 'In the continuation treatment period, one of the treatment arms will be dosed with', 'tralokinumab Q4W. This approach will allow the sponsor of the trial, LEO Pharma A/S', '(hereinafter \"LEO\"), to evaluate whether less frequent dosing of tralokinumab in combination', 'with TCS therapy may be sufficient for maintenance of efficacy.', '5.5 Benefit/risk assessment', 'There is an unmet medical need for new therapies for use in subjects with moderate-to-severe', 'AD as current immunosuppressive medications, such as cyclosporine, methotrexate, and', 'azathioprine, have associated long-term toxicities. Albeit dupilumab exhibits an acceptable', 'benefit-risk ratio in clinical trials in AD, the long-term efficacy and safety experience with', 'dupilumab is currently limited.', 'Tralokinumab has already demonstrated efficacy in both moderate-to-severe AD as well as in', 'a severe asthma population in phase 2 trials, and has shown an acceptable safety profile in', 'AD, asthma, ulcerative colitis, idiopathic pulmonary fibrosis, and in trials with healthy', 'subjects. The evidence discussed in Section 5.2 further supports the hypothesis that', 'individuals with AD may benefit from treatment with tralokinumab.', 'In the clinical trials completed to date, tralokinumab was well tolerated. A number of', 'theoretical potential risks have been identified that are described in the current version of the', \"Investigator's Brochure, including hypersensitivity reactions, immune complex disease,\", 'severe infections, malignancies, and interference with reproductive function; measures are in', 'place in this trial to protect participating subjects as follows:', 'Close monitoring of subjects during the trial with trial visits every 2 weeks', 'during the treatment period (see the schedule of procedures in Section 4).', 'Close monitoring of subjects during the post-dosing period at the first', '3 investigational medicinal product (IMP) dosing visits in the initial treatment', 'period (i.e., Weeks 0, 2, and 4) and after re-randomisation (i.e., Weeks 16, 18,', 'and 20) as a precautionary measure against hypersensitivity reactions (further', 'details are given in Section 9.1.3.1).', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}